Impact of Short Term Lenalidomide on Immune Response to Prevnar 13® in Individuals With Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL), and Monoclonal B Cell Lymphocytosis (MBL)

Trial Profile

Impact of Short Term Lenalidomide on Immune Response to Prevnar 13® in Individuals With Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL), and Monoclonal B Cell Lymphocytosis (MBL)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jun 2016

At a glance

  • Drugs Lenalidomide (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
  • Indications Chronic lymphocytic leukaemia; Lymphocytosis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Jun 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017.
    • 08 Jan 2016 Planned number of patients changed from 76 to 58 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top